Relay Therapeutics Inc

Research Relay Therapeutics Inc (RLAY) on Bullrun: market cap USD 4.30B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerRLAY
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 4.30B
• Financial periodFY2025
• RevenueUSD 15.36M
• Revenue growth53.4%
• Net income-USD 276.48M
• Free cash flow-USD 235.87M

Valuation Snapshot

latest market cap is USD 4.30B.

About Relay Therapeutics Inc

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations;

Frequently asked questions

What is Relay Therapeutics Inc's market cap?

Relay Therapeutics Inc's market capitalization is USD 4.30B.

What does Relay Therapeutics Inc do?

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications.